Intended commercial dose: one 20 mg immediate-release capsule
Phase 3 regimen: second capsule 4 hours or later for persisting or progressing non-laryngeal attacks
Phase 3 regimen: laryngeal attacks
Phase 3 regimen: washout of at least 72 hours between treated attacks
Use of a second capsule in the phase 3 primary efficacy set of 88 participants with paired attacks
Phase 2 dose range: 10, 20, and 30 mg as a single dose of three capsules
Open-label extension regimen: 20 mg in adults and adolescents (RAPIDe-2 part B)
Combined use with the extended-release tablet during prophylaxis: modeled dosing scenarios